Hastings David C

Hastings David C is listed in filings as Chief Financial Officer at Trevi Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jan 12, 2026, including sale activity. Recent filings connect the profile to Trevi Therapeutics, Inc. (TRVI), SCYNEXIS, Inc. (SCYX), and Arbutus Biopharma Corporation (ABUS). The current snapshot covers public activity from Jun 21, 2024 to Jan 12, 2026. Reported amounts are shown as $4.2M to $17.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.